The Pharmaceutical Industry in 2002: Implications of the Pfizer/Pharmacia merger
Big Pharma in 2001/2
Pfizer/Pharmacia: Moving the goalposts

Dynamics of leading pharma players, 2001-07
Growth prospects
Comparative strategic analysis
Generic risk
R&D dependence
Portfolio maturity
Reliance on licensing
Comparative financial analysis
Profitability
Cost ratio analysis
Liquidity

Implications for a new round of mergers and acqusitions
Drivers and resistors to M&A in the pharmaceutical industry
GlaxoSmithKline: the next merger candidate?
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Wyeth

Conclusions

DATASETS
Table 1: Leading pharmaceutical companies by ethical sales, 2001
Table 2: Comparative therapeutic fit: AstraZeneca and GSK
Table 3: Comparative therapeutic fit: BMS and GSK
Table 4: Comparative therapeutic fit: Eli Lilly and GSK
Table 5: Comparative therapeutic fit: Wyeth and GSK